β-receptor antagonist as antihypertensive agent has adverse effect such as vasoconstriction, bronchoconstriction and aggrevation of atherosclerosis. So β-receptor antagonist with α-receptor blocking property has been studied for avoidance of
adverse
effects of β-receptor antagonist. Nipradilol, a new β-receptor antagonist with α-receptor blocking property was administrated in 30 essential hypertensive patients for 10 weeks in order to evaluate the antihypertensive effects and averse
effects.
@ES The Results were as follows:
@EN 1) Nipradilol was effective in 20 patients (67%) on systolic blood pressure and 22 patients (73%) on diastolic blod pressure at the end of 10 weeks treatment.
2) Before medication, mean systolic and diastolic blood pressure in sitting position were 160±14mmHg and 102±18mmHg, and after 10 weeks of medication, mean systolic and diastolic blood pressure were significantly declined to 143±22mmHg and
89±12
mmHg 9P<0.001).
3) There no significant change in pulse rate. from 78±12 beats per minute at the beginning of the treatment to 75±11 beasts per minute after 10 weeks of treatment.
4) There was no significant change in sodium. potassium. GOT, GPT, bilirubin. alkaline phosphatase, BUN, creatinine, LDH, CPK and lipid.
5) The adverse effects of nipradilol were bradycardia (7%), dyspnea (3%), chest discomfort (3%) and headache (3%).
In summary, nipradilol seemed to be effective antihyertensive drug in treating mild to moderate hypertension.
|